The USPTO Issues Notice of Allowance for New Patent Covering MediciNova’s Ibudilast (MN-166) for the Post-COVID Condition
Shots:
- The USPTO has issued a Notice of Allowance to the patent application covering ibudilast for post-COVID conditions (anxiety, fatigue, depression, shortness of breath, PTSD, chest tightness, palpitations, smell or taste dysfunction, sleep difficulties, hair loss & rash); patent once issued will protect it until Nov 2042
- The claims cover ibudilast’s administration alone or in combinations (corticosteroids, NSAIDs, SSRIs) via oral, IV, SC, IM or inhalation methods, covering various doses, frequencies & treatment durations
- Ibudilast, PDE4 & inflammatory cytokines inhibiting small molecule, is in late-stage development for neurodegenerative diseases (ALS, MS & DCM), glioblastoma, Long COVID, CIPN, substance use disorder & ARDS prevention
Ref: MediciNova | Image: MediciNova
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
